Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome.
about
Prognosis and management of acute myeloid leukemia in patients with Down syndromeTranscription factor GATA-1 and Down syndrome leukemogenesisMyelodysplastic syndromes in children. A critical review of the clinical manifestations and management.Improved outcome of acute myeloid leukaemia in Down's syndrome.A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy.Therapy related leukemias: susceptibility, prevention and treatment.Trisomic dose of several chromosome 21 genes perturbs haematopoietic stem and progenitor cell differentiation in Down's syndrome.Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathologyOverexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia.Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia.Bi-allelic deletions within 13q14 and transient trisomy 21 with absence of GATA1s in pediatric acute megakaryoblastic leukemia.Origins of leukaemia in children with Down syndrome.Optimizing therapy for myeloid disorders of Down syndrome.Hematopoietic disorders in Down syndromeThe role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapyRUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia.Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome.Malignancy in children with trisomy 21.Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study.Unique clinical and biological features of leukemia in Down syndrome children.Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.Hematology and oncology at the Hospital for Sick Children.Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.Apoptosis in Down's syndrome: lessons from studies of human and mouse models.AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.Down-syndrome-like acute megakaryoblastic leukemia in a patient with Cornelia de Lange syndrome.Erythromyeloid-Derived TREM2: A Major Determinant of Alzheimer's Disease Pathology in Down Syndrome.Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker.Benign and malignant tumors in Down syndrome: analysis of the 1514 autopsied cases in Japan.GATA1--a player in normal and leukemic megakaryopoiesis.Down syndrome associated childhood myeloid leukemia with yet unreported acquired chromosomal abnormalities and a new potential adverse marker: dup(1)(q25q44).Epidemiologic studies of childhood leukemia: where do we go from here?
P2860
Q27016577-15410455-23BF-4A2F-BC31-236DBABBD801Q28251869-4D3F1EED-6A42-4285-A292-37090A933B54Q33331719-A7F02ED7-2DF8-44B2-B4EB-62D8C50F34EEQ33662916-259DA684-FDC8-45AB-B2D8-6BAFF741F06EQ34081566-EEEB0B76-096F-4AFA-8EAE-69DDD957E47EQ34265193-726C5693-8AD7-4F22-8FBF-BA965713FE0BQ34430274-8D6F323C-8FB4-4E65-B142-6F43176F4D88Q34611232-EBCC5E4A-2609-4C89-8954-6E729D25867FQ34849602-622290E4-6CC7-4818-A15E-9C797CDA7BBCQ35848677-AD854E57-C88E-4629-A28B-DF9DEF9FD5C3Q35896579-2F69316C-85F8-47D6-BED1-8A7AC9E8EC23Q35998756-EEF2BDC3-6475-4201-9E01-8BBFEEE91693Q36262215-74DE6087-271D-44DA-9920-B68CA497CFEDQ36784955-56A15EB2-A946-4BA2-A5A9-62FE29DD82C7Q37259709-94F4F321-DAAB-4D93-9953-05127F70B253Q37372829-F0E6BF7E-2F45-461E-A897-19B80AB3A025Q37372833-6E9CBE2D-8C4F-4341-9718-F166FD584560Q37379570-51DC64FC-E7BA-4D03-AFE8-6638249B9F38Q37552027-E2DFECC3-EA70-4112-9D6E-1A18EBEF7D79Q37810271-A2708106-525A-43D9-8E4E-5D5BB9C97556Q38196743-26431EA8-48DE-407B-81D6-51A889175178Q38733360-51EEA4F5-C859-468D-9561-35272C4B3E55Q39541994-057EDD03-C3A5-4D59-9282-8C62B8FE3D29Q40354450-F0A5442E-F73C-4422-851F-DE999723C55EQ40462682-765C0B0D-FB99-4AE7-953E-9E89BBB3C6DDQ43723779-F1089DCF-AD53-412E-8B3E-CA4C5EAA254BQ46513852-44B44C80-74E0-4ABA-913F-878B489920D5Q47174443-DAB8182A-8E2A-48F6-87E7-C336FDDE13F7Q47253602-3A41D9CD-182B-4BE7-A976-727EACD651DCQ47387633-90989F45-ED06-40DA-ACCC-859BC71A4D0DQ51147270-A37E4435-A8D4-416E-A7C3-E9ED8E31B8FFQ52112289-7F933CC5-31D3-41CC-8782-54EDD3153F89Q52643638-5814A5FA-1DB8-40FB-97DA-249549D9B190Q53427058-AA5239D8-EAA7-455A-BC03-E1F09E1AD373
P2860
Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome.
description
1994 nî lūn-bûn
@nan
1994 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մարտին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome.
@ast
Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome.
@en
type
label
Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome.
@ast
Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome.
@en
prefLabel
Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome.
@ast
Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome.
@en
P2093
P1433
P1476
Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome.
@en
P2093
Christensen H
De Harven E
Zipursky A
P304
P356
10.1016/0145-2126(94)90111-2
P577
1994-03-01T00:00:00Z